Skip to main content
. 2020 Dec 11;12(12):3734. doi: 10.3390/cancers12123734

Figure 5.

Figure 5

Efficacy of PROTAC treatment on ovarian cancer cell growth. (A) SMG 5 cells were treated by PROTAC for 6 h. SAHA, a pan inhibitor of HDACs, was used as a positive control. Degradation efficacy and selectivity of PROTAC was tested by western blot. GAPDH was used as a loading control. Degradation efficacy of 3 μM PROTAC was tested over time. Experiments performed at least n = 2. Uncropped Western Blots are available in Figures S10 and S11 (B) SMG 6 cells were treated by PROTAC for 6 h. Degradation efficacy and selectivity of PROTAC was tested by western blot. GAPDH was used as a loading control. Degradation efficacy of 3 μM PROTAC was tested over time. Experiments performed at least n = 2. Uncropped Western Blots are available in Figures S12 and S13. (C)/(i),(ii) Representative graphs from the real time xCELLigence proliferation system comparing growth profiles of SMG cells following treatment with PROTAC. (C)/(iii),(iv) Cell index values were normalized to both 24 h and control, observing the rate of proliferation (24–96 h). Wells were analyzed in duplicate, and three biological replicates were performed to validate results. Experiments were analyzed by a two-way ANOVA. **** p < 0.0001. Error bars represent SEM. (C)/(i),(iii) SMG5, (C)/(ii),(iv) SMG6. (D) Effect on cell viability after treated by PROTAC for 48 h was determined by MTT assay (n = 3).